K.TalalayP
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
While it won't reverse severe deep wrinkles or significant volume loss like surgical procedures or fillers, it profoundly improves the intrinsic quality of skin tissue
According to Cleveland Clinic, medications that act on GLP-1 approved by the U.S
Clinical data suggest this produces greater average weight loss compared to semaglutide alone
Readers should understand that compounded GLP-1 availability may depend on current federal policy, state rules, individual pharmacy requirements, current shortage status, and clinician judgment